Vitrolife First Quarter 2025 Earnings: Misses Expectations

Vitrolife (STO:VITR) First Quarter 2025 Results

Key Financial Results

• Revenue: kr842.0m (flat on 1Q 2024).
• Net income: kr100.0m (down 13% from 1Q 2024).
• Profit margin: 12% (down from 14% in 1Q 2024).
• EPS: kr0.74 (down from kr0.85 in 1Q 2024).

We check all companies for important risks. See what we found for Vitrolife in our free report.

All figures shown in the chart above are for the trailing 12 month (TTM) period

Vitrolife Revenues and Earnings Miss Expectations

Revenue missed analyst estimates by 3.6%. Earnings per share (EPS) also missed analyst estimates by 15%.

Looking ahead, revenue is forecast to grow 7.2% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Biotechs industry in Sweden.

Performance of the Swedish Biotechs industry.

The company's shares are down 3.0% from a week ago.

Balance Sheet Analysis

While it's very important to consider the profit and loss statement, you can also learn a lot about a company by looking at its balance sheet. We have a graphic representation of Vitrolife's balance sheet and an in-depth analysis of the company's financial position.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.